GlassScriptPhysician profile
Hansen A Chang
NPI 1689735599
$7,345.80
in general payments reported to CMS, 2019-2025
31 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,941 · 2020: $2,490 · 2021: $948 · 2022: $747 · 2023: $617 · 2024: $346 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,345.64 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $1,109.10 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $467.04 | 2019-2025 | Farxiga |
| Abbvie INC. | $405.80 | 2019-2024 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $396.43 | 2019-2025 | Mounjaro, Jardiance, Synjardy |
| Amarin Pharma, INC. | $391.73 | 2019-2021 | |
| Pfizer INC. | $365.60 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $345.35 | 2019-2022 | |
| Gilead Sciences, INC. | $269.77 | 2019-2023 | |
| Eisai INC. | $250.59 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $231.72 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Esperion Therapeutics, INC. | $211.78 | 2020-2022 | |
| Corcept Therapeutics | $200.60 | 2022-2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.64 | 2019-2022 | |
| Ibsa Pharma INC. | $178.91 | 2020-2024 | Tirosint |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $157.19 | 2019 | |
| Lundbeck LLC | $138.54 | 2022-2025 | Vyepti, Rexulti |
| Janssen Pharmaceuticals, INC | $122.87 | 2019 | |
| Sun Pharmaceutical Industries INC. | $116.81 | 2020 | |
| Sumitomo Pharma America, INC. | $95.57 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $69.84 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $47.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $47.63 | 2019 | |
| Glaxosmithkline, LLC. | $45.82 | 2021-2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $33.91 | 2020 | |
| Nestle Healthcare Nutrition INC. | $23.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.09 | 2021 | |
| Alk-Abello, INC | $17.97 | 2022 | |
| Currax Pharmaceuticals LLC | $16.37 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.43 | 2023 | Quviviq |
| Medtronic, INC. | $15.10 | 2024 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hansen Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.